Since their initial study was published in 2013, which focused on KRAS-mutated pancreatic cancer, macropinocytosis has been recognized as a prevalent metabolic feature of other solid tumors, including lung, prostate, bladder and colon cancer, demonstrated by accumulating studies employing different in vitro systems as well as in vivo animal models. Here, KRAS is linked to familial pancreatic carcinoma.